Search PubMed⌕ Search

Biomedical subjects

M H Pollack

Publications and source records attributed to M H Pollack.

At least 109 records · Page 6Linked to original sources
PubMed1987

Clonazepam: a review of open clinical trials.

Data were collected on 50 patients with panic attacks who were treated with clonazepam to determine the drug's antipanic efficacy. At a mean duration of 54.3 weeks, 62% of the patients remained in treatment and 38% were lost to follow-up. Of those remaining in treatment, 90% had a good response to clonazepam and 10% a poor response. The author concludes that clonazepam demonstrated antipanic efficacy, that the development of tolerance or abuse was not a problem, and that most of the patients are being effectively maintained at 2-3 mg/day of clonazepam.

Adult↗
PubMed1987

Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial.

The authors present interim results of a prospective, random assignment, double-blind, placebo-controlled trial conducted to determine whether clonazepam is as effective as alprazolam in reducing the frequency of panic attacks and whether both agents are superior to placebo. Analysis on 44 of 60 randomized subjects showed no statistically significant differences between the clonazepam and alprazolam groups on the following clinically meaningful outcome measures: total number of panic attacks and percent of time subjects experienced anticipatory anxiety, extent of phobic avoidance, and fear. Statistically significant differences did exist among the drug and placebo groups on these measures. The authors conclude that this interim analysis of the data supports the inclusion of clonazepam in the treatment of panic disorder.

Adolescent↗
PubMed1987

Management of antidepressant-induced side effects: a practical guide for the clinician.

The treatment of antidepressant-induced side effects is an important area of clinical concern. Attention to the untoward consequences of pharmacotherapy improves patient compliance and allows the physician to treat patients with the appropriate medication at an efficacious dosage. Based upon review of the literature and clinical experience, a general guide is offered to help the clinician determine treatment strategies that may be effective in dealing with some of the more commonly encountered side effects of the heterocyclic antidepressants and monoamine oxidase inhibitors.

Acute Disease↗
PubMed1986

Enhancement of ECT benefit by yohimbine.

Three patients with major depression who were pretreated with yohimbine 10 mg p.o. showed a dramatic response without major adverse effects following two electroconvulsive treatments (ECT). The hypothesis that the alpha 2-adrenergic antagonist yohimbine accelerates ECT-induced postsynaptic beta-adrenergic receptor down-regulation is discussed.

Administration, Oral↗
PubMed1986

Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up.

Fifty patients with panic disorder or agoraphobia with panic attacks with treated with clonazepam, a high potency benzodiazepine. The authors report on the outcome of these patients after an average follow-up interval of 1 year, suggesting that clonazepam is a safe, effective, and easy to administer medication in a relatively treatment-refractory population of nondepressed patients with panic disorder and agoraphobia.

Adolescent↗
PubMed1985

Propranolol and depression revisited: three cases and a review.

The occurrence of major depressive episodes as complications of treatment with propranolol has been a matter of controversy. Three cases are reported of depressions meeting DSM-III criteria following administration of propranolol for medical conditions. Possible relationships between beta blockade and affective illness are discussed.

Aged↗
PubMed1985

Treatment-emergent incontinence with lithium.

Four (17%) of 23 consecutive female outpatients developed significant urinary or urgency incontinence when treated with lithium carbonate. The symptoms remitted or abated with the addition of oxybutynin (an anticholinergic drug), imipramine, or with decreased lithium dosing. A proposed mechanism involves lithium-induced changes in bladder cholinergic-adrenergic balance.

Adult↗